Analyst consensus rating

Passage Bio Analyst Rating: Buy

Direct answer

Passage Bio's consensus rating is Buy.

2 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $15.50.
Forecast evidence checked November 16, 2026.

Get free Passage Bio email updates.

Bullstory sends one daily email when new analysis or important company news is available.

Verified data

Current price
$4.25
Average price target
$15.50
High price target
$23.00
Low price target
$8.00
Low target gap
+88.2%
Target upside
+264.7%
High target gap
+441.2%
Target range width
352.9%
Consensus rating
Buy
Analysts
2
Evidence date
November 16, 2026
Valid through
November 23, 2026

Read the frequently asked questions.

What is the analyst consensus rating for Passage Bio?

Passage Bio has a verified Buy consensus. The same dataset has an average price target of $15.50.

How far are Passage Bio's low and high targets from the recorded price?

The low target implies +88.2%, while the high target implies +441.2%.

How many analysts are included in Passage Bio's consensus?

The verified consensus includes 2 analysts.

How is Passage Bio's target upside or downside calculated?

The average target of $15.50 is divided by the recorded price of $4.25, then one is subtracted to produce +264.7%. This does not guarantee a future return.

When was Passage Bio's analyst forecast verified?

The data was verified on 2026-11-16. The dataset is valid through 2026-11-23.